BioCryst Pharmaceuticals
BCRX
7.22
-0.10
-1.37%
BioCryst Pharmaceuticals
US · BCRX
#2766 by market cap
Listed 1970
7.22
-0.10
-1.37%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Quant vs Street three independent views, side by side
StockVane factor grade
B
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1 1
■ Upgrades■ Downgrades
- 1 upgrade vs 1 downgrade among tracked analyst rating changes.
- Most recent: RBC Capital moved from Buy to Hold on 2026-09-10.
Analyst consensus 6 analysts
Buy
Avg price target 17.00 +135.5%
Price target rangecurrent 7.22
Low11.00
Avg17.00
High30.00
Buy 67%
Hold 33%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-05 | Wedbush | -- | Buy | 17.00 |
| 2026-11-04 | RBC Capital | -- | Hold | 11.00 |
| 2026-10-21 | TD Cowen | -- | Buy | 30.00 |
| 2026-10-09 | BofA Securities | -- | Buy | 15.00 |
| 2026-10-08 | RBC Capital | -- | Hold | 11.00 |
| 2026-09-30 | J.P. Morgan | -- | Hold | 13.00 |
| 2026-09-10 | RBC Capital | -- | Hold | 11.00 |
| 2026-09-08 | Needham | -- | Buy | 16.00 |
| 2026-08-06 | Wedbush | -- | Buy | 20.00 |
| 2026-08-06 | H.C. Wainwright | -- | Buy | 32.00 |
| 2026-08-05 | TD Cowen | -- | Buy | 30.00 |
| 2026-08-05 | Needham | -- | Buy | 16.00 |
| 2026-08-05 | RBC Capital | -- | Buy | 13.00 |
| 2026-07-15 | BofA Securities | -- | Buy | 15.00 |
| 2026-07-13 | Wedbush | -- | Buy | 21.00 |
| 2026-07-13 | J.P. Morgan | -- | Hold | 12.00 |
| 2026-07-07 | RBC Capital | -- | Buy | 14.00 |
| 2026-06-30 | Cantor Fitzgerald | -- | Buy | 29.00 |
| 2026-06-30 | Wedbush | -- | Buy | 21.00 |
| 2026-06-30 | Needham | -- | Buy | 16.00 |
| 2026-06-30 | H.C. Wainwright | -- | Buy | 32.00 |
| 2026-06-29 | Needham | -- | Buy | 16.00 |
| 2026-05-07 | Wedbush | -- | Buy | 21.00 |
| 2026-05-07 | Citizens JMP | -- | Buy | 28.00 |
| 2026-05-07 | H.C. Wainwright | -- | Buy | 32.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-09-10 | RBC Capital | Buy → Hold | 11.00 |
| 2026-02-18 | Evercore | Hold → Buy | 17.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-04 | -- | ±15.39% | -3.85% (in line) |
| 2026/Q2 | 2026-08-05 | -- | ±11.90% | +0.55% (in line) |
| 2026/Q1 | 2026-05-06 | -- | ±10.52% | -2.21% (in line) |
| 2025/Q4 | 2026-02-26 | -- | ±8.74% | +4.64% (in line) |
| 2025/Q3 | 2025-11-03 | -- | ±16.39% | -6.28% (in line) |
| 2025/Q2 | 2025-08-04 | -- | ±16.93% | +9.81% (in line) |
| 2025/Q1 | 2025-05-05 | -- | ±11.67% | +23.52% (beat) |
| 2024/Q4 | 2025-02-24 | -- | ±15.83% | -9.99% (in line) |
| 2024/Q3 | 2024-11-04 | -- | ±15.08% | -12.81% (in line) |
| 2024/Q2 | 2024-08-05 | -- | ±17.02% | +6.98% (in line) |
| 2024/Q1 | 2024-05-06 | -- | ±17.53% | +18.43% (beat) |
| 2023/Q4 | 2024-02-26 | -- | ±24.27% | +1.40% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.
BioCryst Pharmaceuticals discussion 0 comments